Tag: Chinese plasma sector
CSL to buy majority stake in a leading Chinese plasma fractionator
Australian biotech firm CSL has agreed to acquire an 80% stake in China’s plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (Ruide) in...
Featured Article
Future-ready manufacturing: How AI and cloud ERP are transforming supply chains
As manufacturers face growing supply chain disruption, rising costs and increasing operational complexity, artificial intelligence (AI), cloud ERP and connected digital systems are becoming essential tools for improving visibility, resilience and decision-making.
